Titre : Antagonistes du récepteur de type 1 de l'angiotensine-II

Antagonistes du récepteur de type 1 de l'angiotensine-II : Questions médicales fréquentes

Termes MeSH sélectionnés :

Early Detection of Cancer
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Antagonistes du récepteur de type 1 de l'angiotensine-II : Questions médicales les plus fréquentes", "headline": "Antagonistes du récepteur de type 1 de l'angiotensine-II : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Antagonistes du récepteur de type 1 de l'angiotensine-II : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-21", "dateModified": "2025-04-15", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Antagonistes du récepteur de type 1 de l'angiotensine-II" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Antagonistes des récepteurs aux angiotensines", "url": "https://questionsmedicales.fr/mesh/D057911", "about": { "@type": "MedicalCondition", "name": "Antagonistes des récepteurs aux angiotensines", "code": { "@type": "MedicalCode", "code": "D057911", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.519.162" } } }, "about": { "@type": "MedicalCondition", "name": "Antagonistes du récepteur de type 1 de l'angiotensine-II", "alternateName": "Angiotensin II Type 1 Receptor Blockers", "code": { "@type": "MedicalCode", "code": "D047228", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None None", "url": "https://questionsmedicales.fr/author/None%20None", "affiliation": { "@type": "Organization", "name": "" } }, { "@type": "Person", "name": "Tadashi Namisaki", "url": "https://questionsmedicales.fr/author/Tadashi%20Namisaki", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan. tadashin@naramed-u.ac.jp." } }, { "@type": "Person", "name": "Kosuke Kaji", "url": "https://questionsmedicales.fr/author/Kosuke%20Kaji", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan." } }, { "@type": "Person", "name": "Naotaka Shimozato", "url": "https://questionsmedicales.fr/author/Naotaka%20Shimozato", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan." } }, { "@type": "Person", "name": "Yukihisa Fujinaga", "url": "https://questionsmedicales.fr/author/Yukihisa%20Fujinaga", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, Nara Medical University, Shijo-cho 840, Kashihara, Nara, 634-8522, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.", "datePublished": "2022-09-24", "url": "https://questionsmedicales.fr/article/36153587", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12957-022-02766-0" } }, { "@type": "ScholarlyArticle", "name": "Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.", "datePublished": "2022-09-13", "url": "https://questionsmedicales.fr/article/36098904", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jcla.24692" } }, { "@type": "ScholarlyArticle", "name": "Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.", "datePublished": "2022-09-08", "url": "https://questionsmedicales.fr/article/36088216", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jgo.2022.08.020" } }, { "@type": "ScholarlyArticle", "name": "Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.", "datePublished": "2022-07-15", "url": "https://questionsmedicales.fr/article/35856081", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s43856-022-00155-y" } }, { "@type": "ScholarlyArticle", "name": "Early Mortality among Patients with Head and Neck Cancer Diagnosed in Thuringia, Germany, between 1996 and 2016-A Population-Based Study.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35804871", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/cancers14133099" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Mécanismes moléculaires de l'action pharmacologique", "item": "https://questionsmedicales.fr/mesh/D045504" }, { "@type": "ListItem", "position": 5, "name": "Antagonistes des récepteurs aux angiotensines", "item": "https://questionsmedicales.fr/mesh/D057911" }, { "@type": "ListItem", "position": 6, "name": "Antagonistes du récepteur de type 1 de l'angiotensine-II", "item": "https://questionsmedicales.fr/mesh/D047228" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Antagonistes du récepteur de type 1 de l'angiotensine-II - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Comment diagnostiquer une hypertension ?\nQuels tests pour évaluer l'efficacité des ARA ?\nQuels signes indiquent une insuffisance cardiaque ?\nComment évaluer les effets secondaires des ARA ?\nQuand faire un ECG chez un patient sous ARA ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Quels symptômes nécessitent un avis médical urgent ?\nQuels effets secondaires courants des ARA ?\nComment reconnaître une hypotension ?\nQuels symptômes d'une réaction allergique aux ARA ?\nQuels signes d'une hyperkaliémie ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Comment prévenir l'hypertension ?\nLe tabagisme influence-t-il l'hypertension ?\nL'alcool affecte-t-il la pression artérielle ?\nComment le stress impacte-t-il la santé cardiaque ?\nQuels aliments éviter pour contrôler la pression ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Comment fonctionnent les ARA ?\nQuels sont les ARA les plus prescrits ?\nQuand débuter un traitement par ARA ?\nLes ARA sont-ils sûrs pendant la grossesse ?\nComment ajuster la dose d'ARA ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Quelles sont les complications de l'hypertension ?\nComment l'hypertension affecte-t-elle les reins ?\nQuels risques d'AVC liés à l'hypertension ?\nL'hypertension peut-elle causer des problèmes oculaires ?\nQuels effets de l'hypertension sur le cœur ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Antagonistes du récepteur de type 1 de l'angiotensine-II", "description": "Quels sont les principaux facteurs de risque d'hypertension ?\nLe diabète influence-t-il l'hypertension ?\nL'hérédité joue-t-elle un rôle dans l'hypertension ?\nLe manque d'exercice est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D047228?mesh_terms=Early+Detection+of+Cancer&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une hypertension ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension est diagnostiquée par des mesures répétées de la pression artérielle." } }, { "@type": "Question", "name": "Quels tests pour évaluer l'efficacité des ARA ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de pression artérielle et des analyses sanguines pour surveiller les électrolytes sont effectués." } }, { "@type": "Question", "name": "Quels signes indiquent une insuffisance cardiaque ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Essoufflement, fatigue, œdèmes et palpitations peuvent indiquer une insuffisance cardiaque." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires des ARA ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier des symptômes et des tests sanguins pour les électrolytes est nécessaire." } }, { "@type": "Question", "name": "Quand faire un ECG chez un patient sous ARA ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un ECG est recommandé si le patient présente des symptômes cardiaques ou des anomalies de pression." } }, { "@type": "Question", "name": "Quels symptômes nécessitent un avis médical urgent ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des douleurs thoraciques, des difficultés respiratoires ou des évanouissements doivent être évalués." } }, { "@type": "Question", "name": "Quels effets secondaires courants des ARA ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent des vertiges, des maux de tête et des troubles gastro-intestinaux." } }, { "@type": "Question", "name": "Comment reconnaître une hypotension ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des étourdissements, une vision floue et une fatigue excessive." } }, { "@type": "Question", "name": "Quels symptômes d'une réaction allergique aux ARA ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées, des démangeaisons ou un gonflement peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Quels signes d'une hyperkaliémie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des palpitations, une faiblesse musculaire et des picotements peuvent signaler une hyperkaliémie." } }, { "@type": "Question", "name": "Comment prévenir l'hypertension ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée, l'exercice régulier et la gestion du stress aident à prévenir l'hypertension." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il l'hypertension ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme augmente le risque d'hypertension et de maladies cardiovasculaires." } }, { "@type": "Question", "name": "L'alcool affecte-t-il la pression artérielle ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une consommation excessive d'alcool peut entraîner une augmentation de la pression artérielle." } }, { "@type": "Question", "name": "Comment le stress impacte-t-il la santé cardiaque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut contribuer à l'hypertension et à d'autres problèmes cardiaques." } }, { "@type": "Question", "name": "Quels aliments éviter pour contrôler la pression ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé d'éviter les aliments riches en sodium et en graisses saturées." } }, { "@type": "Question", "name": "Comment fonctionnent les ARA ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les ARA bloquent les récepteurs de l'angiotensine-II, réduisant ainsi la pression artérielle." } }, { "@type": "Question", "name": "Quels sont les ARA les plus prescrits ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les ARA courants incluent le losartan, le valsartan et l'irbésartan." } }, { "@type": "Question", "name": "Quand débuter un traitement par ARA ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement par ARA est débuté lorsque d'autres antihypertenseurs sont inefficaces ou mal tolérés." } }, { "@type": "Question", "name": "Les ARA sont-ils sûrs pendant la grossesse ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les ARA sont généralement contre-indiqués pendant la grossesse en raison de risques pour le fœtus." } }, { "@type": "Question", "name": "Comment ajuster la dose d'ARA ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La dose est ajustée en fonction de la réponse du patient et des effets secondaires observés." } }, { "@type": "Question", "name": "Quelles sont les complications de l'hypertension ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent les maladies cardiaques, les AVC et les lésions rénales." } }, { "@type": "Question", "name": "Comment l'hypertension affecte-t-elle les reins ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension peut endommager les vaisseaux sanguins des reins, entraînant une insuffisance rénale." } }, { "@type": "Question", "name": "Quels risques d'AVC liés à l'hypertension ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension augmente le risque d'accident vasculaire cérébral ischémique et hémorragique." } }, { "@type": "Question", "name": "L'hypertension peut-elle causer des problèmes oculaires ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner des lésions rétiniennes et des problèmes de vision." } }, { "@type": "Question", "name": "Quels effets de l'hypertension sur le cœur ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer une hypertrophie du cœur, des arythmies et une insuffisance cardiaque." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque d'hypertension ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, l'obésité, le tabagisme et une alimentation riche en sodium." } }, { "@type": "Question", "name": "Le diabète influence-t-il l'hypertension ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diabète augmente le risque d'hypertension et de complications cardiovasculaires." } }, { "@type": "Question", "name": "L'hérédité joue-t-elle un rôle dans l'hypertension ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux d'hypertension augmentent le risque individuel." } }, { "@type": "Question", "name": "Le manque d'exercice est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire contribue à l'augmentation de la pression artérielle." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à l'hypertension et à d'autres problèmes de santé." } } ] } ] }

Sources (10000 au total)

Pathological and oncological outcomes of pylorus-preserving versus conventional distal gastrectomy in early gastric cancer: a systematic review and meta-analysis.

Pylorus-preserving gastrectomy (PPG) is a function-preserving surgery for the treatment of early gastric cancer (EGC) in the middle third of the stomach. According to the literature reports, PPG decre... The protocol was registered in PROSPERO under number CRD42022304677. Databases including PubMed, Embase, Web of Science, and the Cochrane Register of Controlled Trials were searched before February 21... A total of 4500 patients from 16 studies were included. Compared with the CDG group, the PPG group had fewer lymph nodes harvested (WMD= -3.09; 95% CI -4.75 to -1.43; P < 0.001). Differences in the nu... The meta-analysis of existing evidence demonstrated that the survival outcomes of PPG may be comparable to those of CDG. However, fewer lymph nodes at stations in No. 5, No. 6, No. 9, and No. 11p were...

Ornithine aminotransferase and carbamoyl phosphate synthetase 1 involved in ammonia metabolism serve as novel targets for early stages of gastric cancer.

The sensitivity and specificity of current biomarkers for gastric cancer were insufficient. The aim of the present study was to screen novel biomarkers and determine the diagnostic values of ornithine... With stable isotope tags, we labelled an initial discovery group of four paired gastric cancer tissue samples and identified with LC-ESI-MS/MS. A validation group of 159 gastric cancer samples and 30 ... Four hundred and thirty one proteins were found differentially expressed in gastric cancer tissues. Of these proteins, OAT and CPS1 were found over-expressed in gastric cancer patients, with sensitivi... The present findings indicated a tight correlation between the co-expression of OAT and CPS1 and the histological grade, local invasion, and TNM stages of gastric cancer. Therefore, OAT and CPS1 might...

Patient characteristics and health system factors associated with adjuvant radiation therapy receipt in older women with early-stage endometrial cancer.

Among women with early-stage endometrial cancer (EC), age, stage, grade, and histology are used to determine fitness for adjuvant radiation therapy (RT) administration. We examined non-cancer factors ... Using data from the Surveillance Epidemiology and End Results cancer registry program linked with Medicare claims, we identified 25,654 women (aged ≥66 years) diagnosed with first primary stage I-II E... Adjuvant RT was less commonly administered to Asian American and Pacific Islander patients than non-Hispanic White patients (Prevalence ratio [PR], 0.84; 95% confidence interval [CI], 0.73 to 0.97). C... Findings suggest that various non-cancer factors affect the delivery of adjuvant RT to older women with early-stage EC in real-world oncology practice. Advancing our understanding of factors associate...

Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer.

Treatment for metastatic colorectal cancer patients beyond the second line remains challenging, highlighting the need for early phase trials of combination therapies for patients who had disease progr... MORPHEUS-CRC is an umbrella, multicenter, open-label, phase Ib/II, randomized, controlled trial (NCT03555149), with active experimental arms ongoing. Patients enrolled were assigned to a control arm (... The experimental arm showed no efficacy signal, yet a well-tolerated safety profile in the MORPHEUS-CRC trial. Treatment effects estimated in hybrid control design were comparable to those in the MORP... Hybrid control provides comparable treatment-effect estimates with generally improved precision, and thus can be of value to inform early-phase clinical development in metastatic colorectal cancer....

Construction and validation of N6-methyladenosine long non-coding RNAs signature of prognostic value for early biochemical recurrence of prostate cancer.

Early biochemical recurrence (eBCR) indicated a high risk for potential recurrence and metastasis in prostate cancer. The N6-methyladenosine (m6A) methylation modification played an important role in ... Pearson correlation analysis was first conducted to explore m6A lncRNAs and univariate Cox regression analysis was further performed to identify m6A lncRNAs of prognostic roles for predicting eBCR in ... Five hundred and thirty-eighth m6A lncRNAs were searched out through Pearson correlation analysis and 25 out of 538 m6A lncRNAs were identified to pose prediction roles for eBCR in prostate cancers. A... The m6A lncRNA signature in this study could be utilized to efficiently predict eBCR occurrence, various clinical characteristic and immune microenvironment for prostate cancer....

MRI characteristics of breast edema for assessing axillary lymph node burden in early-stage breast cancer: a retrospective bicentric study.

To investigate whether breast edema characteristics at preoperative T2-weighted imaging (T2WI) could help evaluate axillary lymph node (ALN) burden in patients with early-stage breast cancer.... This retrospective study included women with clinical T1 and T2 stage breast cancer and preoperative MRI examination in two independent cohorts from May 2014 to December 2020. Low (< 3 LNs+) and high ... A total of 1092 patients were included in this study. BES was identified as the independent predictor of pALN burden in primary (n = 677) and validation (n = 415) cohorts. The analysis using MRI-ALN s... In individuals with early-stage breast cancer, preoperative MRI characteristics of breast edema could be a promising predictor for pALN burden, which may aid in treatment planning.... • In this retrospective study of 1092 patients with early-stage breast cancer from two cohorts, the MRI characteristic of breast edema has independent and additive predictive value for assessing axill...

A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.

To evaluate the value of combined detection of serum CA125, CA199, and HE4 in the diagnosis of ovarian cancer.... Relevant articles retrieved from PubMed, Elsevier Science, Springer, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases were screened strictly according to inclusion and exclus... The results of meta-analysis showed that there was a statistical difference in diagnostic specificity analysis of CA125 (OR = 1.91, 95% CI (1.58, 2.32),... In the clinical assisted diagnosis of ovarian cancer, combined detection of CA125, CA199, and HE4 has the stronger discriminant ability and higher accuracy than single detection of CA125, which can im...

BMI increase during early childhood in boys with cystic fibrosis and early adrenarche.

Increase in body mass index (BMI) in early childhood (1-6 years) was found to be a contributing factor for impaired final height in boys with Cystic Fibrosis (CF). Early adrenarche (before age 9 years... Boys with CF, aged 8-9 years, visiting the CF expertize center Utrecht were included. Since 2018, anthropomorphic, pubertal and endocrine data were collected. Early adrenarche in boys was defined as a... Thirteen boys (mean age 8.55 ± 0.27 years) were enrolled. The median (IQR) DHEAS-level was 1.3 µmol/L (0.71-2.40). Eight boys (61.5%) had an early rise in DHEAS-levels ≥ 1 µmol/L. Mean increase in BMI... In this small cohort, 61.5% of boys with CF between 8 and 9 years had an early rise of DHEAS, which was correlated to ΔBMI...